Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SafeHer
2011-005328-17Phase 3Completed
- Sponsor
- Roche
- Start
- Feb 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label trial of trastuzumab in breast cancer (2 cohorts), sponsored by Roche. Primary endpoint: Overall safety and tolerability. Started Feb 2012; status: completed.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2011-005328-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-005328-17.